Dysfunction of autonomic nervous system is an important non motor feature of Parkinson' disease (PD). Lewy body formation is widely distributed in hypothalamus and in sympathetic and parasympathetic systems. Animal studies suggest a link between hypothalamus sensing of substrates and glucose metabolism. Thus, hypothalamus lesions could lead to change in glucose metabolism. Recently, we showed that fasting blood glucose level was significantly higher in PD patients than in control group suggesting that glucose tolerance may be impaired in PD. Some studies provided evidence for higher diabetes prevalence in PD patients whereas others showed no difference or a reduced risk of diabetes prevalence in PD patients compared to healthy subjects. So, the risk that a PD patient develops a glucose intolerance or a diabetes is not clearly established and merit to be studied considering the damageable consequences for patient healthy. The aim of this prospective study was to determine the risk that a PD patient develop a glucose intolerance or a diabetes compared to a matched control group, using an oral glucose tolerance test (OGTT).
50 patients Inclusion visit : * Clinical examination/ Interview on health and medical history * Complete UPDRS, MMS * Biologic check up Protocol : All patients were studied in the postabsorptive state after a 10-h overnight fast. On the day of the experiment, patients did not receive their treatment. One catheter was inserted for blood sample collections. Patients ingested then 75 g of glucose. Blood samples were collected for plasma glucose and plasma insulin concentration analyses at T0, T30, T60, T90, T120, T150 and T180. Urinary glucose was researched at T0 and T120. In parallel, a dysautonomia evaluation of each patient was made (SCOPA AUT questionnaire, Tilt test).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
50
Protein and calorie controlled diet Self-hypnotic relaxation
CHU Clermont-Ferrand
Clermont-Ferrand, France
NOT_YET_RECRUITINGChu Clermont-Ferrand
Clermont-Ferrand, France
RECRUITINGThe primary outcome is the plasma glucose concentration measured 120 min after the oral glucose surcharge intake.
Time frame: 120 min after the oral glucose surcharge intake.
Plasma insulin concentration kinetic
Time frame: at T0, T30, T60, T90, T120, T150 and T180
Plasma glucose concentration kinetic
Time frame: at T0, T30, T60, T90, T120, T150 and T180
Urinary glucose measurement
Time frame: at T0 and T120
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.